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Abstract
Background Chronic heart failure (CHF) is increasing in
prevalence. Patients with CHF usually have co-morbid
conditions, but these have been subjected to little research
and consequently there is a paucity of guidance on how to
manage them. Obesity and diabetes mellitus are common
antecedents of CHF and often complicate management and
influence outcome. Cachexia is an ominous and often
missed sign in patients with CHF.
Methods This manuscript describes the rationale and the
design of Studies Investigating Co-morbidities Aggravating
Heart Failure (SICA-HF), a prospective, multicentre,
multinational, longitudinal, pathophysiological evaluation
study, which is being conducted in 11 centres across six
countries in the European Union and in Russia. We aim to
recruit >1,600 patients with CHF due to various common
aetiologies, irrespective of left ventricular ejection fraction,
and with or without co-morbidities at study entry. In
addition, >300 patients with type 2 diabetes mellitus
without CHF and >150 healthy subjects will serve as
control groups. Participants will be systematically investi-
gated at annual intervals for up to 48 months. Additional
investigations focusing on cellular and subcellular mecha-
nisms, adipose and skeletal muscle tissue, and in endothe-
lial progenitor cells will be performed in selected
subgroups.
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Conclusions SICA-HF will provide insights into common
co-morbidities in CHF with a specific emphasis on diabetes
mellitus and body mass. This will provide a more thorough
pathophysiological understanding of the complexity of
CHF that will help develop therapies tailored to manage
specific co-morbidities.
Keywords Heart failure . Pathophysiology . Diabetes
mellitus . Obesity . Cachexia
1 Introduction
Chronic heart failure (CHF) poses a massive clinical, social
and economic problem. It has been estimated that approx-
imately 14 million people are affected in the European
Union [1] and 5 million in the United States [2]. The
average survival in epidemiological representative patient
cohorts may be as poor as 3 years, suggesting that there
may be >2 million new cases of heart failure in the
European Union alone each year. Although there have been
significant advances in the treatment of the disease over the
last 20 years, CHF is still not curable, despite treatment
aimed at limiting its progression [1, 2]. Altogether, the
treatment of CHF consumes a greater percentage of healthcare
costs than human immunodeficiency virus infection or cancer
[3–5]. The last several years have seen growing research
interest into subgroups of patients with the disease who are
deemed to benefit from tailored therapies. This is particularly
true for patients who have CHF and co-morbidities such as
anaemia [6], renal failure [7], catabolic/anabolic imbalance
[8] or atrial fibrillation [9]. In addition, dyssynchrony has
recently received increasing research interest [10, 11].
Patients with CHF have different phenotypes, and those
with left ventricular systolic dysfunction due to ischemic
heart disease have been most intensively investigated [1, 2];
however, they represent <50% of patients managed in
everyday practice [12, 13], and thus we still do not have
sufficient insight into disease mechanisms, natural course
and management of the majority of patients with CHF.
There are several subgroups of patients with CHF that have
received little systematic research so far. This particularly
holds true for patients at the extreme ends of the body
weight spectrum, i.e. patients with cardiac cachexia or
obesity, as well as patients with type 2 diabetes mellitus.
They have, so far, been treated as if their co-morbidities
were not present, and current guidelines do not differentiate
between such subgroups. A thorough understanding of the
pathophysiological processes could hold the key to improve
their management.
The importance of cardiac cachexia has long been
underestimated in clinical practice [14]. Among 171
unselected patients with CHF, mortality rates were as high
as 50% in the cachectic subset compared to 17% in the
non-cachectic subset at 18 months of follow-up [15].
Overall, there is a scarcity of data on the prevalence and
incidence of cachexia and obesity in patients with CHF, and
only small studies have been reported so far [16]. In
contrast with the widely accepted public belief that obesity
shortens life expectancy, patients with CHF and a higher
body mass index (BMI) may have better outcomes
compared to those with a “normal” BMI in terms of a
decreased risk of death and hospitalisation. This so-called
“obesity paradox” has been shown in several databases of
CHF [16, 17] and other cardiovascular diseases [18, 19],
but no prospective data are available so far.
Overt diabetes mellitus is another common co-morbidity
in patients with CHF, and the EuroHeart Failure Survey
reported an incidence as high as 27% [20]. The prevalence
of this co-morbidity ranges between 20% and 30% in
prospective large-scale studies of ambulatory heart failure
[21, 22], and elevated levels of glycated haemoglobin have
been shown to be strong predictors of mortality among
patients with heart failure [23]. Even less is known about
insulin resistance, which also is common and predicts a
worse prognosis [23, 24].
Little is known about the characteristics of these
subgroups of CHF patients or about the effects of physical
exercise [25], nutrition [26, 27] or drug therapies [28] on
them. Neither do we know much about differences in
commonly used biomarkers such as N-terminal pro-B-type
natriuretic peptide nor about the effects of co-morbidities
on measures of cardiac function such as left ventricular
ejection fraction, cardiac output, exercise capacity and
cardiorespiratory reflex control. The interplay between
skeletal muscle, adipose tissue and other tissues or the
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pathophysiology of the responsible mediators is poorly
researched.
The paucity of data with regard to heart failure and its
co-morbidities and between the interplay of different tissues
in this clinical syndrome has led to the design of the Studies
Investigating Co-morbidities Aggravating Heart Failure
(SICA-HF). This article gives details about the rationale,
design and methodology of SICA-HF.
2 Methods
2.1 Study design
SICA-HF is a prospective, multicentre, multinational,
longitudinal, pathophysiological evaluation study, which is
being conducted in 11 centres across six countries. SICA-
HF receives funding from the European commission’s
Seventh Framework Programme (FP7/2007–2013) under
grant agreement no. 241558 (SICA-HF) and from the
Russian Ministry of Science and Education within the FTP
“R&D in priority fields of the S&T complex of Russia
2007–2012” under state contract number 02.527.11.0007.
The participating centres are shown in Fig. 1; the study
design is summarised in Fig. 2. The study is conducted in
accordance with the Declaration of Helsinki principles and
local/national regulations. National and/or local ethics
committees revised and approved the study protocol. A
patient’s written informed consent is mandatory prior to
inclusion and any study-related procedure.
2.2 Eligibility
At baseline, patients will be screened for inclusion into the
study. The aim of SICA-HF is to include a broad range of
patients with CHF with or without co-morbidities at study
entry. Both patients with preserved or reduced ejection
fraction are eligible. Patients of any aetiology of CHF can
be enrolled into SICA-HF. The inclusion/exclusion criteria
as specified in Table 1 reflect these concepts.
2.3 Planned clinical investigations and follow-up
SICA-HF aims to recruit >1,600 patients with CHF. In
addition, we will enrol subjects into two control groups,
>300 patients with type 2 diabetes mellitus without CHF
but at risk of developing heart failure and >150 healthy
subjects without obvious risk of developing heart failure.
All subjects will undergo a systematic cardiological
evaluation, including echocardiography, resting electrocar-
diogram, full blood count and routine biochemistry
analysis. Subjects will undergo a thorough clinical exam-
ination as detailed below. In addition, we aim to harvest
adipose tissue samples, skeletal muscle and bone marrow
Fig. 1 Participating centres in SICA-HF
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by biopsy in selected patients. These samples will be used
for ex vivo and in vitro studies that are also described
below. About 50% of patients with heart failure are women,
but they are generally underrepresented in studies of heart
failure, mainly because patients with left ventricular
ejection fraction (LVEF) >40% have been excluded.
Epidemiologically, about 70% of patients with LVEF
<40% are men but 60% of patients with LVEF >40% are
women. SICA-HF will recruit patients with a broad
spectrum of LVEF, and therefore, we expect about half of
all patients should be women, consistent with the known
epidemiology [29].
2.3.1 Body composition analysis
In order to understand body composition and its changes
over time in patients with CHF, SICA-HF will utilise two
principal approaches to body composition analysis: first,
body impedance assessment (BIA), and second, dual
energy X-ray absorptiometry (DEXA) scanning. BIA is
easily applicable to large patient cohorts using inexpensive
equipment, and it provides information on the whole body;
hence, it will be possible to use this technology in all
Screening for eligibility
Signed informed consent
Age >18 years
Heart failure patients Healthy controlsType 2 Diabetes Mellitus
N>1600 N>150N>300
Diagnosis of heart failure No chronic disease
AND at least one
Diagnosis of Type 2 Diabetes Mellitus
At risk of heart failure
- left ventricular ejection fraction 40%
- left atrial dimension >4.0cm (>2.5cm/m height)
NTproBNP >400pg/ml OR BNP >150pg/ml-
Data collection at baseline
Data collection at follow-up
6 8 h-  mont s
12 months
24 months
36 months
48 h mont s
>
Fig. 2 Overview of SICA-HF
Table 1 Inclusion and exclusion criteria of SICA-HF
Inclusion criteria:
Clinical diagnosis of heart failure
Objective evidence of cardiac dysfunction as evidenced
by at least one of the following:
Left ventricular ejection fraction ≤40%
Left atrial dimension >4.0 cm (or >2.5 cm/m in height)
NT-proBNP >400 pg/ml (>47.3 pmol/l) (or BNP >150 pg/ml)
Age >18 years
Willingness to provide informed consent
Exclusion criteria:
Previous heart transplantation
History of unstable angina, myocardial infarction, stroke,
cardiovascular revascularization or open abdominal surgery
within 6 weeks prior to the planned baseline visit
Known pregnancy
Patients on haemodialysis at baseline
Unable to understand and comply with protocol or to
give informed consent
NT-proBNP N-terminal pro-B-type natriuretic peptide
190 J Cachexia Sarcopenia Muscle (2010) 1:187–194
recruited patients. DEXA scanning is a more precise
method that requires the use of significantly more expen-
sive equipment that can provide body composition results
for the whole body as well as any region of interest.
2.3.2 Peripheral blood flow
Peripheral blood flow and vascular reactivity will be
assessed in the setting of CHF and the association
specifically to insulin sensitivity and metabolic and
hormonal regulation. Using venous occlusion (strain gauge)
plethysmography, we will measure peripheral blood flow of
the leg and of the forearm at rest, as post-ischemic peak
blood flow and as flow-dependent flow.
2.3.3 Exercise testing and cardiopulmonary reflex research
Patients who are able, will undergo exercise testing, in most
cases, using spiroergometry. In addition to standard parame-
ters (peak oxygen consumption, ventilatory efficiency), we
are planning to analyse numerous other parameters, including
an integrative response in ventilation, oxygen consumption
and carbon dioxide production, and heart rate during exercise
and during recovery. Additionally, patients will undergo a
comprehensive assessment of cardiopulmonary reflex control,
including heart rate and blood pressure control, baroreflex,
chemoreflex and ergoreflex sensitivity.
2.3.4 Insulin resistance
Non-diabetic subjects are scheduled to undergo whole-body
insulin sensitivity testing using a 3-h intravenous glucose
tolerance test and minimal modelling technique. Patients
will be studied under standardised conditions (start in the
morning, fasting, supine position, quiet room). After
administration of a weight-adjusted glucose bolus intrave-
nously, repeated serum samples will be obtained for profiles
of glucose, insulin and C-peptide. From these profiles,
individual insulin sensitivity can be assessed using the
minimal modelling approach [30]. Assessment of the
homeostasis model assessment, a reflection of insulin
sensitivity and fasting plasma glucose will additionally be
performed in a larger cohort of >500 subjects who have
been prospectively recruited at the University of Hull after
referral for suspected left ventricular dysfunction.
2.3.5 Sleep-disordered breathing
Two types of sleep-disordered breathing are common
among patients with heart failure—obstructive sleep
apnea–hypopnea (OSAH) and Cheyne–Stokes breathing
(CSB). Risk factors for sleep-disordered breathing in patients
with CHF vary according to the type of sleep-disordered
breathing. With respect to CSB, risk factors include male
gender, advanced age, atrial fibrillation and hypocapnia (i.e.
transcutaneous carbon dioxide ≤38mmHg) [31]. With respect
to OSAH, risk factors include advanced age and increasing
BMI. Sleep-disordered breathing is best conceptualized as a
sequence of events. In an effort to correct the hypocapnia, a
hypersensitive respiratory control center initiates apnea. This
occurs when the PaCO2 is below the “apneic threshold”. The
PaCO2 then begins to rise. The duration from the beginning
of the apnea until the respiratory control centre detects the
increasing PaCO2 is prolonged due to the increased
circulatory time caused by the heart failure. Participating
patients will be screened for sleep-disordered breathing using
a standardised questionnaire, an ambulatory sleep–apnoea
screening device and a 24-h ECG monitoring recorder with
the measurement of peripheral oxygen saturation.
2.3.6 Blood and deoxyribonucleic acid bank
Subjects enrolled into SICA-HF will have blood samples
taken to analyse biomarkers and gene profile in order to
identify tools for diagnostic, prognostic and therapeutic
guidance.
2.4 Investigations of metabolic and cellular mechanisms
SICA-HF aims to elucidate pathways that mediate tissue
wasting and obesity in CHF by studying the interplay
between muscle and adipose tissue wasting in cardiac
cachexia and the role of skeletal muscle, an important factor
for insulin resistance, in type 2 diabetes mellitus.
Adipose tissue samples will be obtained by liposuction
in a subgroup of patients in SICA-HF and will serve as a
basis for understanding the interplay between blood and
tissue markers. Two potential mechanisms mediate loss of
adipose tissue in cachexia: increased lipolysis or reduced
lipogenesis [28]. Fat cells are sensitive to the lipolytic
effects of atrial and B-type natriuretic peptides, both of
which are found at elevated plasma concentrations in CHF
[32]. Insulin is a key anti-lipolytic agent.
Skeletal muscle biopsies will be obtained in a subgroup of
SICA-HF subjects using the Bergström needle technique. In
cachexia, skeletal muscle is lost mainly by proteolysis, which
is mediated by different mechanisms, including lysosomal
(cathepsins) and calcium-dependent (calpains) pathways, the
caspase system, matrix metalloproteinases and the adenosine
triphosphate-dependent ubiquitin–proteasome system [25].
The latter plays a dominant role in myofibrillar protein
breakdown [28]; however, data on patients with CHF are
scarce.
Another important task of SICA-HF is to study the roles
of circulating progenitor cells in patients with CHF in terms
of their blood concentration, relationship to the clinical
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severity of the disease, measures of heart function, and
clinical outcomes. SICA-HF will investigate associations
between circulating progenitor cells (as a reflection of
the degree of endothelial dysfunction) and circulating
angiogenic or anti-angiogenic growth factors and pro-
inflammatory cytokines. Most of these substances have
been shown to mobilise EPCs from the bone marrow.
Subjects participating in SICA-HF are scheduled for
follow-up visits after 6–8 months and annually thereafter
until the study terminates. The total duration of SICA-HF is
48 months. In accordance with local availability, not all the
above tests can be performed in all participating centres.
2.5 Objectives
Using the above-described techniques, SICA-HF (http://
www.sica-hf.com) is designed to evaluate the following
primary objectives:
Objective 1: To characterise the prevalence, incidence,
persistence and phenotype of obesity, cachexia and
type 2 diabetes in patients with CHF
Objective 2: To describe patterns of exercise capacity
and cardiorespiratory reflex control
Objective 3: To analyse body composition and its
changes over time in patients with CHF and type 2
diabetes, obesity or cachexia
Objective 4: To investigate the incidence and preva-
lence of sleep-disordered breathing and its impact on
the clinical severity in patients with CHF
Objective 5: To establish the impact of impaired
vascular reactivity on impaired skeletal muscle meta-
bolic and functional capacity, including its underlying
mechanisms
Objective 6: To describe the interplay and metabolic
signalling pathways between adipose tissue, skeletal
muscle, the bone marrow and the heart in patients with
heart failure and type 2 diabetes, obesity and cachexia
3 Discussion
SICA-HF is the first large-scale multicenter project to
systematically collect information about the natural history
of CHF and its interplay with three important and common
co-morbidities: type 2 diabetes mellitus, cachexia and
obesity. Importantly, SICA-HF embraces clinical and basic
science research methodologies. One of the principle ideas
of SICA-HF is that basic researchers will be provided with
biomaterials such as adipose tissue and skeletal muscle
biopsies from patients who have undergone a detailed,
systematic set of clinical investigations. This will provide a
wealth of information helping to understand cellular and
molecular mechanisms and to extend this knowledge into
translation to clinical parameters.
Another important consideration in designing SICA-HF
was to enrol patients irrespective of their LVEF. This is
important because patients with preserved LVEF have
received little scientific attention so far. Epidemiological
and clinical characterisation, as well as therapeutic
management, are much better established for patients with
left ventricular systolic dysfunction. We do not know
whether available evidence can be extrapolated to patients
with preserved left ventricular ejection fraction [33].
Clustering of features of the metabolic syndrome,
especially arterial hypertension may be particularly
common in such patients. A recent study in 1,236
patients with heart failure and preserved ejection fraction,
44% of whom had a BMI>30 kg/m2 found an increasing
prevalence of arterial hypertension and diabetes mellitus
across groups with increasing BMI [34]. Low BMI was
associated with poorest survival, similar to previous
observations in patients with left ventricular systolic
dysfunction. Morbid obesity (BMI>45 kg/m2), however,
also represented an increased risk, and a U-shaped
relationship between BMI and mortality was described.
Secondary analysis of the Digitalis Investigation Group
ancillary trial (988 patients with LVEF >45%) focused on
diabetes mellitus and reported a prevalence of 29% among
patients with preserved LVEF [35]. Diabetics were more
likely to be women, to have a history of hypertension and
a higher BMI. Adverse CHF-related outcomes, including
cardiovascular mortality and hospitalizations, were more
common in diabetics. In an adjusted model, diabetes was
associated with a 68% increased risk of hospitalisation for
heart failure or heart failure-associated death [hazard ratio
(HR) 1.68; 95% confidence interval (CI), 1.26–2.25].
Information about cachexia in CHF with preserved left
ventricular ejection fraction is, to the best of the authors’
knowledge, lacking, as well is information about body
composition and a potential interplay with clinically
detectable metabolic changes. Clustering of metabolic
issues is known as the metabolic syndrome, which is
associated with an increased risk for cardiovascular
complications, including the incidence of heart failure
[36]. In the general population, aggressive management is
warranted whereas no guidance has been published for
patients with CHF. Conversely, physicians are inclined to
extrapolate knowledge from the general population or from
patients with coronary artery disease without heart failure to
patients who already suffer from overt heart failure.
Available data about the metabolic syndrome in CHF is
scarce and with certain methodological drawbacks. A
retrospective study in 886 patients [37] used the National
Cholesterol Education Program Expert Panel criteria with a
BMI≥30 kg/m2 substituted for increased waist circumference
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to confirm the presence of the metabolic syndrome in 625
(71%) patients. In a fully adjusted model, presence of the
metabolic syndrome conferred, in contrast to the general
population but in line with reverse epidemiology, a protec-
tive mortality effect (HR, 0.73; 95% CI, 0.56–0.94). It is
evident that CHF has a clinically important metabolic
component, but the applicability of the current metabolic
syndrome definition [38] to patients with CHF has been
challenged [39]. SICA-HF has the potential for in-depth
investigations of metabolic issues and associated mecha-
nisms to evaluate their effect on pathophysiology and
outcome. The prospective design will allow to control for
changes over time and to assess the implications for clinical
presentation of CHF.
CHF is associated with activation of several mecha-
nisms and body systems. Neurohormonal activation
initially has protective effects but prolonged (over-)
activity translates into clinically apparent damage medi-
ated through neurohormonal and other mechanisms. This
seems to be particularly important in the setting of
cachexia, when highest concentrations of natriuretic
peptides and markers of inflammation are detected [40].
Our knowledge about the activation and the interplay of
existing systems [27, 41] and the level of induction
remains insufficient, particularly so among patients with
preserved left ventricular ejection fraction. Nonetheless,
different organs are no longer considered as separated
entities with specific and limited functions but rather as a
well-controlled and interactive system. Even fat tissue,
which was considered merely as an energy depot, emerges
as a sophisticated endocrine organ with precisely adjusted
function and effects beyond fat tissue itself [42]. Adipo-
nectin, for instance, a collagen-like plasma protein
produced by adipose tissue, which has in general anti-
atherogenic and anti-inflammatory effects, is elevated in
patients with CHF [43], which seems to be mediated
through natriuretic peptides [44]. Data from preclinical
experiments suggest that hypoadiponectinemia in
hypertension-induced diastolic heart failure exacerbates
left ventricular hypertrophy, diastolic dysfunction and
diastolic heart failure [45]. Whether this has applications
in patients and whether adiponectin replacement could be
a novel therapeutic approach to prevent the progression to
diastolic heart failure warrants further study.
SICA-HF will be the first detailed, systematic,
longitudinal, international, epidemiological study of
CHF, providing insights into the progression of cardio-
vascular and metabolic dysfunction and their relationship
to outcome in patients with CHF. Thus, SICA-HF is a
unique living laboratory that will help redefine CHF as a
clinical entity and improve treatment of both cardiovas-
cular and metabolic components of the disease in the
next few decades.
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